VNRX VolitionRX
- 0.750
- -0.128-14.53%
VolitionRX News
VolitionRx Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
VolitionRx Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results.
VolitionRX Is Maintained at Buy by EF Hutton
VolitionRX Is Maintained at Buy by EF Hutton
VolitionRX | 10-Q: Quarterly report
VolitionRX 1Q Rev $170,000 >VNRX
VolitionRX 1Q Rev $170,000 >VNRX
Press Release: VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update PR Newswire HENDERSON, Nev., May 13, 2024 Conference call to discuss financial and operational results schedule
VolitionRX Q1 2024 Earnings Preview
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., May 8, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it wil
VolitionRX Announces Board Reshuffle and Bylaws Amendment
VolitionRX (VNRX) has shared an announcement.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by
VolitionRx Shares Are Trading Higher After the Company Announced the Availability of Its Nu.Q Vet Cancer Test in the US and Europe.
VolitionRx Shares Are Trading Higher After the Company Announced the Availability of Its Nu.Q Vet Cancer Test in the US and Europe.
VolitionRx Announces Its Nu.Q Vet Cancer Test Is Now Available In-Clinic Across US And Europe Through Antech
VolitionRx Announces Its Nu.Q Vet Cancer Test Is Now Available In-Clinic Across US And Europe Through Antech
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
EF Hutton analyst Tim Moore maintains VolitionRX with a Buy and maintains $4.5 price target.
VolitionRX Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 500.56% EF Hutton $4.5 → $4.5 Maintains Buy 01/02/2024 500.56% EF Hutton $4.5 → $4.5 Reiterates
Earnings Call Summary | VolitionRX(VNRX.US) Q4 2023 Earnings Conference
The following is a summary of the VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript:Financial Performance:VolitionRx recorded revenue of $775,000 for the full year 2023, a significantly highe
VolitionRX Reports FY Results
VolitionRX Q4 EPS $(0.11), Inline, Sales $243.97K Miss $450.00K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 15.38 percent increase over losses of $(0.13) per share from the same period l
VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
Financial HighlightsCash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022.Recorded approximately $775,000 in reven
Press Release: VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update PR Newswire HENDERSON, Nev., March 25, 2024 Conference call to discuss financial and operational results sch
Earnings Scheduled For March 25, 2024
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. • Syra Health (NASDAQ:SYRA) is likely to report
Analysis
Price Target
No Data
